Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: Implications for therapy

Martin K H Maus, Philip Mack, Stephanie H. Astrow, Craig L. Stephens, Gary D. Zeger, Peter P. Grimminger, Jack H. Hsiang, Eric Huang, Tianhong Li, Primo N Lara, Kathleen D. Danenberg, David R Gandara

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


INTRODUCTION: On the basis of the results of recent clinical trials, histology-based decision-making for therapy of non-small-cell lung cancer has been advocated. We hypothesized associations of the biomarkers excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) with histology as a contributing factor to reported differences in chemotherapy outcomes between squamous cell carcinoma (SCCA) and adenocarcinoma (AC) subtypes. Here, we report analysis of the Response Genetics Inc., database and implications for histology-based therapy. METHODS: RNA from microdissected formalin-fixed paraffin-embedded tumors was extracted and analyzed as previously described. Specimens from 2540 individual non-small-cell lung cancer patients were analyzed for one or more biomarkers, of which 1457 were categorized as AC or SCCA. RESULTS: For each biomarker, gene expression was lower in AC compared with SCCA (<0.001), although there was a wide range between individual patients. Gene expression was higher in men versus women: ERCC1: 2.51 versus 2.22 (p = 0.005); RRM1: 1.41 versus 1.24 (p = 0.004); TS: 3.23 versus 2.83 (p < 0.001). However, SCCA was more frequent in men versus women (30%/19%; p < 0.001). When AC and SCCA were assessed separately, the statistical significance between gene expression and sex was lost (in SCCA: ERCC1, p = 0.14; RRM1, p = 0.26; TS, p = 0.11). CONCLUSIONS: This analysis represents the largest data set for gene expression of these biomarkers reported so far. Significant histology-related associations for ERCC1, RRM1, and TS are seen. However, marked heterogeneity exists in individual patient tumor expression levels. Randomized phase III trials assessing the predictive value of these chemotherapy-related biomarkers are warranted.

Original languageEnglish (US)
Pages (from-to)582-586
Number of pages5
JournalJournal of Thoracic Oncology
Issue number5
StatePublished - May 2013


  • Biomarkers in NSCLC
  • ERCC1
  • Histology
  • Personalized treatment
  • RRM1
  • Sex
  • TS

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine


Dive into the research topics of 'Histology-related associations of ERCC1, RRM1, and TS biomarkers in patients with non-small-cell lung cancer: Implications for therapy'. Together they form a unique fingerprint.

Cite this